Welcome to our dedicated page for Mirati Therapeutics news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial stage biotechnology company focused on pioneering breakthrough therapies to transform the lives of patients with cancer. Specializing in molecularly targeted and immuno-oncology combination therapies, Mirati is at the forefront of cancer treatment innovation. The core of Mirati's mission is to develop drug candidates that target genetic and epigenetic drivers of cancer. The company leverages a strategic approach that includes selecting patients whose tumors depend on specific genetic alterations and employing a highly accomplished leadership team in oncology precision medicine.
Mirati Therapeutics is advancing three primary drug candidates through clinical development for multiple oncology indications. Their flagship product, KRAZATI® (adagrasib), has shown promising results in treating non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation. Adagrasib offers potential best-in-class efficacy, particularly for patients with central nervous system metastases. Notably, the drug has been granted conditional marketing authorization by the UK's MHRA and the European Commission, highlighting its impactful role in current cancer treatment paradigms.
Mirati's innovative pipeline also includes MRTX1719, a PRMT5 inhibitor, and MRTX1133, a selective KRASG12D inhibitor, both of which are designed to address high unmet medical needs. The company recently completed an upsized public offering, extending its cash runway to support upcoming milestones.
In recent developments, Mirati announced that Laurie Stelzer, Chief Financial Officer, will depart the company in September 2023, with Aaron Ondrey stepping in as interim CFO. This transition comes at a pivotal time as Mirati continues to advance its clinical programs and prepare for potential new product launches.
With a relentless focus on patient outcomes, Mirati's vision is to unlock the science behind a life beyond cancer. The company continues to collaborate with global healthcare regulators and partners to ensure broad access to its groundbreaking therapies.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced significant preclinical findings for its targeted oncology treatments, MRTX0902 and MRTX1719. The data, to be presented at the AACR 2023 Annual Congress on
Mirati Therapeutics, Inc. (NASDAQ: MRTX) will participate in the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m. E.T..
Mirati Therapeutics (NASDAQ: MRTX) reported its fourth quarter and full-year 2022 financial results, highlighting the FDA approval of KRAZATI™ for KRASG12C-mutated non-small cell lung cancer. The company holds approximately $1.1 billion in cash as of December 31, 2022. Net product revenue for Q4 and the full year was $0.7 million, with a notable decline in license and collaboration revenue to $11.7 million from $72.1 million in 2021. Research and development expenses increased to $531.6 million, marking a rise from $508.6 million in 2021. The net loss widened to $740.9 million, or $13.18 per share, compared to $581.8 million in the previous year.
Mirati Therapeutics (NASDAQ: MRTX) will participate in the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 11:10 a.m. PT. CEO David Meek will represent the company during a fireside chat. Investors and the public can access a live webcast through the Investors and Media section on Mirati.com, with a replay available afterward.
Mirati is a biotechnology firm focused on developing targeted therapies for cancer, particularly lung cancer. Their mission is to deliver breakthrough treatments that address significant unmet needs in the oncology space.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) will announce its fourth quarter and full year financial results for 2022 on February 28, 2023. A conference call is scheduled for 4:30 p.m. ET, where executives will discuss the results and recent corporate updates. Interested parties can access the call via a live webcast or by dialing in. As a targeted oncology company, Mirati focuses on developing therapies for high unmet needs in cancer treatment, particularly in lung cancer. The company emphasizes innovation and aims to deliver transformative therapies for patients.
On February 3, 2023, Mirati Therapeutics (NASDAQ: MRTX) announced the granting of equity awards to four new employees as part of its Inducement Plan. These awards, essential for recruitment, include options for 11,590 shares and 7,190 restricted stock units (RSUs). The option exercise price is $52.69, reflective of the closing stock price on the grant date. The options will vest over four years, while the RSUs will vest at 25% annually after the first year. This initiative complies with Nasdaq Listing Rule 5635(c)(4), demonstrating Mirati's commitment to aligning employee interests with shareholder value.
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an oncology-focused biotechnology company, announced its participation in two healthcare conferences. On February 8, executives Laurie Stelzer and Alan Sandler will engage in a fireside chat at the Guggenheim Healthcare Talks: Oncology Day Conference at 7:45 a.m. PT. The following week, on February 14, they will represent the company at the SVB Securities Global Biopharma Conference at 2:00 p.m. PT. Interested parties can access live webcasts through the "Investors and Media" section on Mirati's website. The company aims to deliver groundbreaking therapies for cancer patients, focusing on high unmet medical needs.
Mirati Therapeutics (NASDAQ: MRTX) announced FDA clearance for its Investigational New Drug (IND) application for MRTX1133, a first-in-class oral selective inhibitor targeting the KRASG12D mutation, affecting approximately 180,000 patients in the US and Europe. This marks the third KRAS program entering clinical development for Mirati. MRTX1133 demonstrated significant preclinical efficacy in models of pancreatic, lung, and colorectal cancers. The Phase 1/2 clinical trial is set to commence in early 2023, exploring multiple expansion cohorts. The company aims to address a significant unmet need in cancer treatment.
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will present at the 41st J.P. Morgan Annual Healthcare Conference on January 9, 2023, at 9:00 a.m. P.T. / 12:00 p.m. E.T.. CEO David Meek will lead the presentation, followed by a Q&A session. A live webcast will be accessible on Mirati.com. Mirati focuses on innovative cancer therapies addressing high unmet needs, including lung cancer.
The FDA has granted Breakthrough Therapy Designation for adagrasib (KRAZATI) in combination with cetuximab, aimed at treating patients with KRASG12C-mutated advanced colorectal cancer who have not responded to prior therapies. This designation is based on promising results from the Phase 1b cohort of the KRYSTAL-1 trial, showing an objective response rate of 46% and a median duration of response of 7.6 months. Additionally, findings published in NEJM indicate favorable safety and tolerability for this combination therapy.
FAQ
What is the market cap of Mirati Therapeutics (MRTX)?
What does Mirati Therapeutics specialize in?
What are the main drug candidates of Mirati Therapeutics?
What recent approvals has KRAZATI® received?
Who is the interim Chief Financial Officer of Mirati Therapeutics?
What is the focus of Mirati's drug development strategy?
Where can I find more information about Mirati's clinical trials?
How does Mirati's adagrasib (KRAZATI) differ from other cancer treatments?
What recent corporate updates has Mirati announced?
What is the mission of Mirati Therapeutics?
How can investors contact Mirati Therapeutics?
